Introduction {#Sec1}
============

Palmoplantar psoriasis (PP) is a chronic, debilitating disease of the palms and/or soles that affects 11--39% of psoriasis patients \[[@CR1]--[@CR3]\]. The morphology of PP can range from thick, hyperkeratotic plaques with fissuring to pustular lesions of the palms and/or soles, and PP is often classified into subtypes based on this morphologic distinction \[[@CR4], [@CR5]\]. Hyperkeratotic PP refers to sharply defined erythematous scaly plaques with overlying hyperkeratosis and without the presence of sterile pustules, predominantly at the palms and/or soles \[[@CR6]\]. Pustular PP is a variant that includes macroscopic sterile pustules and erythema with intermixed yellow--brown macules localized to the palms and/or soles \[[@CR6]\]. PP causes greater physical discomfort and functional disability than psoriasis limited to other body areas, and it is often recalcitrant to treatment \[[@CR2]\].

Palmoplantar pustulosis (PPP) is a bilateral, symmetric dermatosis that also affects the hands and/or feet and is clinically distinguished from PP based on the absence of psoriasis at other body sites and a predilection for histologic involvement of the acrosyringium (the terminal duct of eccrine sweat glands) \[[@CR6], [@CR7]\]. Pustular PP and hyperkeratotic PP mostly occur concomitantly with psoriasis at other body areas, while PPP consists of pustular lesions typically limited to the palms and/or soles that appear on a clear, non-erythematous background \[[@CR6]--[@CR8]\]. However, whether PPP can be considered a clinical spectrum of plaque psoriasis or whether it is an independent disease is open to much debate. Consequently, in the literature, pustular PP and PPP are often not well distinguished. Some studies have identified the involvement of the acrosyringium as being more specific to PPP \[[@CR7], [@CR9]\]. Demographically, PPP is characterized by a female predominance and strong association with smoking, whereas no such associations exist for pustular PP \[[@CR6], [@CR7]\]. Interestingly, in individuals with PPP, nicotine is thought to be secreted into eccrine glands to promote inflammation and alter the local response to infection \[[@CR7]\]. Recent genetic studies have challenged the relationship of PPP with plaque psoriasis, although both these conditions can respond to similar treatments and have a similar impact on quality of life.

Topical therapy and phototherapy are first-line modalities for the management of PP and PPP. However, the majority of patients eventually require treatment with systemic medications \[[@CR3]\]. Traditionally, agents such as oral retinoids, methotrexate, and cyclosporin have been utilized, but these medications carry risks of adverse effects that may limit their use in clinical practice.

Biologic agents have been well studied for the treatment of moderate to severe chronic plaque psoriasis, but less is known about the efficacy of these medications for the treatment of PP and PPP. We have therefore performed a systematic review of the use of biologic agents for the treatment of hyperkeratotic PP, pustular PP, and PPP with the aim to provide clinicians with helpful information when considering management options for these disabling conditions.

Methods {#Sec2}
=======

The biomedical and healthcare journal databases of Ovid National Library of Medicine's Medical Literature Analysis and Retrieval System (MEDLINE), Embase, and the Cochrane Library were searched to identify published articles that assessed the efficacy and safety of biologic agents for the treatment of hyperkeratotic PP, pustular PP, and PPP. The detailed search strategy is presented in Electronic Supplementary Material Fig. 2. Abstracts were screened, and articles that appeared to meet the inclusion criteria were assessed further. Reference lists of relevant articles were scrutinized to identify additional reports.

Eligibility Criteria {#Sec3}
--------------------

Publications were included if subjects were diagnosed with PP or PPP based on the assessment by the authors of each publication and if subjects received treatment with one of the currently approved biologics for psoriasis, namely, adalimumab, brodalumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, or ustekinumab. Publications were required to report the efficacy and/or safety outcomes of the biologic treatment. Publications describing the treatment of cases of PPP induced by exposure to biologic medications were excluded due to the likely distinct pathophysiology of drug-induced PPP.

Study Selection and Data Extraction {#Sec4}
-----------------------------------

Three reviewers (E.S., I.S., E.L.) independently conducted publication selection (Fig. [1](#Fig1){ref-type="fig"}). Any discrepancies were resolved by an additional reviewer (W.L.). Studies were categorized based on the morphology of palmoplantar lesions. Study characteristics (author, year of publication, design, number of patients, intervention, duration of treatment, outcome, and key safety indicators) and subject characteristics (age, sex, comorbidities, morphological variant, severity at baseline, involvement of sites other than the palms and soles, and prior treatments) were extracted using a standardized data abstraction form designed for this review. Efficacy outcomes were recorded in Table [1](#Tab1){ref-type="table"}, defined as a 50% reduction in the PPP Area and Severity Index (PPASI-50) if available, otherwise a 75% reduction in PPASI (PPASI-75) or an Investigator Global Assessment (IGA) score of 0/1 (cleared/minimal disease) was used. If two biologics were studied in one study, both were described in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} under the category of the primary biologic that was studied, but the efficacy data of both biologics were used to calculate the summary of clinical improvement outcomes in Table [5](#Tab5){ref-type="table"}. Due to the heterogeneity of outcome measures, outcomes were reported as described by the authors of each publication.Fig. 1Process of study selection

Compliance with Ethics Guidelines {#Sec5}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec6}
=======

The initial search yielded 731 articles. After excluding duplicates, we screened 579 reports by title and abstract, of which identified 76 articles for full-text review. Following the full-text review, we ultimately included 44 publications reporting the use of a biologic medication in the treatment of PP and PPP in the analysis, seven and two of which were randomized controlled trials (RCTs) and open-label trials, respectively (Table [1](#Tab1){ref-type="table"}) \[[@CR10]--[@CR22]\]. The remaining publications were case reports or case series \[[@CR20]--[@CR53]\].Table 1Hyperkeratotic palmoplantar psoriasis, efficacy and safety of biologic agentsReference, type of studyNumber of subjectsTreatmentTreatment durationOutcomeSafety/commentsAdalimumab  Leonardi 2011 \[[@CR14]\], Double-blind randomized placebo-controlled trial722:1 adalimumab 80 mg SC at week 0 and 40 mg SC q 2 weeks thereafter vs. placebo16 weeks30.6% (15) adalimumab-treated subjects achieved hfPGA of 0 or 1 at week 16 vs. 4.3% (1) placebo-treated subject (*p* = 0.01)No AEs reportedAlefacept  Myers 2005 \[[@CR21]\], case report2Alefacept (15 mg IM once weekly)12 weeks(1) complete resolution at 5 weeks;\
(2) improvement at 10 weeks, reduced scaling, redness, inflammation, plaque thicknessNo AEs reported; 2 = some recurrence when alefacept stopped, requiring restarting treatment for 10 additional weeksEtanercept  Meyer 2011 \[[@CR25]\], case report1Alitretinoin 30 mg PO daily + etanercept 50 mg SC weekly13 monthsMarked reduction within 4 weeks, complete resolution in 8 weeksNo AEs reportedGuselkumab  Blauvelt 2017 \[[@CR15]\], VOYAGE1 RCT100 (subset of 837 psoriasis patients)Guselkumab (2:1:2 randomization, 100 mg at week 0, 4, then q 8 weeks) or placebo to guselkumab (placebo weeks 0, 4, 12 then guselkumab weeks 16, 20 then q8 weeks), or adalimumab 80 mg week 0, then 40 mg week 1, then 40 mg q 2 weeks)16^a^, 24, or 48 weeks^a^At week 16, guselkumab 73.3% reached IGA 0/1 vs. adalimumab 55.8%, vs. placebo 14%; week 24, guselkumab IGA 0/1 78.9% vs. adalimumab 56.8%; week 48, guselkumab IGA 0/1 75.6% vs. adalimumab 62.1%Overall cohort: Nasopharyngitis, URI, cellulitis (2 in adalimumab group), basal cell carcinoma (1 in guselkumab group), 2 myocardial infarctionsInfliximab  Bissonnette 2011 \[[@CR13]\], double-blind randomized placebo-controlled trial241:1 infliximab 5 mg/kg IV at week 0, 2, 6, 14, 22 vs. placebo at weeks 0, 2, 6, then infliximab at weeks 14, 16, 2014^a^ or 22 weeksAt week 14, 33.3% achieved m-PPPASI-75 and 66.7% achieved m-PPPASI-50 vs. 8.3% for either (*p* = 0.317 and *p* = 0.009); 50.3% reduction in mean surface area vs. 14.9% increase with placebo3 SAEs: 1 hepatitis, 1 cellulitis, 1 sternum fracture  Brunasso 2012 \[[@CR33]\], case series5Infliximab 5 mg/kg at weeks 0, 2, 6, and every 8 weeks thereafter30 weeksAt week 14, mean m-PPPASI improved 27.69%; at week 30, mean m-PPPASI improved 41.2%No AEs reported; compared changes in m-PPPASI with PASI: PASI improved 86.8% and 89.11% at weeks 14 and 30, respectivelyIxekizumab  Menter 2017 \[[@CR17]\], UNCOVER RCT206Ixekizumab (1:1:1 randomization, 160 mg at week 0, 80 mg every 2 or 4 weeks); etanercept (2:2:2:1 randomization, 160 mg ixekizumab at week 0, then 80 mg every 2 or 4 weeks, 50 mg etanercept twice weekly)12^a^, 48, or 60 weeksAt week 12, PPASI improvement of 80% with ixekizumab vs. placebo (28.1%) or vs. etanercept (53%) (*p* \< 0.05 for all comparisons) Greater PPASI-50 improvement with ixekizumab (80%) vs. placebo (32.9%) or vs. etanercept (67.8%). Greater PPASI-75 improvement with ixekizumab (70%) vs. placebo (18.8%) or vs. etanercept (44.1%), (*p* \< 0.05 for all comparisons)No AEs reportedSecukinumab  Gottlieb 2017 \[[@CR16]\], GESTURE RCT137Secukinumab (1:1:1 randomization, 300 mg, 150 mg or placebo)16 weeksPPIGA 0 (clear) or 1 (minimal): 33.3% with 300 mg regimen, 22.1% with 150 mg regimen, 1.5% on placebo (*p* \< 0.001 and *p* = 0.002, respectively vs. placebo). DLQI 0/1 higher w secukinumab 300 mg (26.6%) and 150 mg (16.9%) vs. placebo (1.5%), *p* \< 0.0001 and *p* \< 0.005SAEs: 150 mg 5.9%, 300 mg 2.9%, placebo 2.9%; AEs (40): Headache (17), naropharyngitis (11), URI (10), Candida (3)  Paul 2014 \[[@CR18]\], RCT103 (46 patients in early regimen)Secukinumab (1:2:2:1 randomization, 150 mg SC of either single (week 0), monthly (weeks 0, 4, 8), early (weeks 0, 1, 2, 4) or placebo)12 weeksIGA response of 0 (clear) or 1 (minimal) + improvement of ≥ 2 points; Early regimen response: 54.0%No AEs reportedUstekinumab  Heinecke 2013 \[[@CR41]\], case series2 (subset of 22 psoriasis patients)Ustekinumab 45 mg or 90 mg SC at weeks 0, 4, and every 12 weeks thereafter + acitretin PONot describedBoth patients demonstrate "excellent control" with only mild scalingNo AEs related to PP subjects reported  Nuno-Gonzalez 2012 \[[@CR42]\], case report1Ustekinumab 45 mg SC at weeks 0, 4, and every 12 weeks thereafter12 monthsComplete resolution at 16 weeks, maintained clear at 12 monthsNo AEs reported  Bulai Livideanu 2010 \[[@CR43]\], case series2Ustekinumab 45 mg and 90 mg SC respectively at weeks 0, 4, and every 12 weeks thereafter(1) 7 months (2) 4 months(1) Dramatic improvement at 7 months, localized PPASI improved by 85%; (2) Palms cleared at 1 month, good clinical improvement and localized PPASI improved 65% at 4 monthsNo AEs reported*AE* Adverse event, *BSA* body surface area, *DLQI* Dermatology Life Quality Index, *F* female,*hfPGA* Physician Global Assessment of the hand and foot, *HTN* hypertension,*IGA* Investigator Global Assessment,*IM* intramuscular, *IV* intravenous, *M* male, *m-PPPASI* modified Palmoplantar Pustulosis Area and Severity Index, *PASI* Psoriasis Area and Severity Index, *PGA* Physician Global Assessment,*PO* orally, *PP* palmoplantar psoriasis,*PPIGA* palmoplantar psoriasis Investigator Global Assessment, *PPP* palmoplantar pustulosis,*PsA* psoriatic arthritis, *PUVA* psoralen + ultraviolet A,*q* every,*RCT* randomized controlled trial, *SAE* serious adverse event, *SC* subcutaneous, *URI* upper respiratory infection *UVA* ultraviolet A, *UVB* ultraviolet B^a^Primary endpoint of study

A total of 722 cases of hyperkeratotic PP, 63 cases of pustular PP, and 58 cases of PPP were included in the analysis. Almost all patients in the included studies were adults. The specifics of age, gender, comorbidities, and previous therapies are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The previous use of systemic therapy was not consistently reported in all patients. Many patients received prior systemic therapy and some had received prior biologic therapy. Several subjects had responded to phototherapy, and nearly all had not responded to topical therapy.Table 2Pustular palmoplantar psoriasis, efficacy and safety of biologic agentsReference, type of studyNumber of subjectsTreatmentTreatment durationOutcomeSafety/commentsAdalimumab  Ghate 2009 \[[@CR24]\], case report1Adalimumab 40 mg SC q 2 weeks6 monthsAt week 16, BSA decreased from 4 to 1%, resolution of PsA symptoms; 8 months after d/c, no joint symptoms or PPNo SAEs reported; mild, diffuse scalp alopecia (leading to d/c at 6 months)Etanercept  Ahmad 2007 \[[@CR27]\], case series1 (subset of 49 psoriasis patients)Etanercept 25 mg or 50 mg SC BIWTotal mean 58.2 weeksFailedUnclear  Floristan 2011 \[[@CR28]\], case report1Etanercept 0.4 mg/kg SC BIW for 8 months increased to 0.6 mg/kg SC BIW12 monthsSlow but progressive improvement over first month; at 12 months "striking improvement" of plantar lesionsNo AEs reported  Kitamura 2009 \[[@CR30]\], case report1Etanercept 50 mg SC BIW + efalizumb 80 mg weekly≥ 11 monthsPsoriasis and PsA "very well- controlled" (but pustular PP not responsive to etanercept alone)1 SAE: reactivation TBInfliximab  Kamili 2011 \[[@CR35]\], case series6 (subset of 120 psoriasis patients)Infliximab 5 mg/kg IV at weeks 0, 2, and 6 and every 8 weeks thereafterAt least 1 year2 patients with "complete responses"Unclear  Wozel 2008 \[[@CR37]\], case report1Infliximab 5 mg/kg IV at week 0, 2, and 6 and every 8 weeks thereafter8 months"Marked improvement" 4 days after staring infliximab, with "severe" relapse at 8 monthsNo SAEs reported  Ahmad 2006 \[[@CR39]\], case series1 (series of 12 psoriasis patients)Infliximab 5 mg/kg IV at week 0, 2, 6 and every 8 weeks thereafterNot describedExcellent improvement after third infusionNo SAEs reported; discontinued due to elevated liver function testsUstekinumab  Morales-Munera 2013 \[[@CR45]\], case series5Ustekinumab 45 mg SC at weeks 0, 4, and every 12 weeks thereafterMean 15.2 months, range 11--23 monthsAll patients with positive response 2-3 weeks after first dose, all with complete resolution at week 20 maintained to date with no flaresNo AEs reported  Buder 2016 \[[@CR51]\], case series9Ustekinumab (45 mg if \< 100 kg body weight, 90 mg if \> 100 kg body weight at weeks 0, 4, 12, 24)24 weeksAfter 24 weeks, 44.4% reached PPASI-75, 22.2% reached PPASI-100, PPASI improvement was 71.6%; goal: improve PPASI by 75% after 12 weeks or improve DLQI by 5 pointsNo AEs reported; recurrence in 1 patient required stopping treatment and switching to golimumab with improvement*BIW* Twice weekly, *d/c* discontinued*DM* diabetes mellitus, *TB* tuberculosis, *PPD* purified protein derivative, *HCV* hepatitis C Table 3Palmoplantar pustulosis, efficacy and safety of biologic agentsReference, type of studyNumber of subjectsTreatmentTreatment durationOutcomeSafety/commentsAdalimumab  Olazagasti 2017 \[[@CR22]\], retrospective cohort study8Adalimumab, etanercept, infliximab1996--2013Partial response to adalimumab (2; no response to adalimumab (2); no response to etanercept (3); partial response to infliximab (1)No AEs reported  He 2012 \[[@CR23]\], case report1Adalimumab 40 mg SC q 2 weeks + methotrexate 15 mg weekly1 monthResponse of PP not describedNo SAEs reported; acneiform eruption, alopecia areata, and urticaria after third injection leading to d/cEtanercept  Bissonnette 2008 \[[@CR12]\], Double-blind randomized placebo-controlled trial152:1 etanercept 50 mg SC BIW week 0-24 vs. placebo weeks 0--12 then etanercept 50 mg SC BIW weeks 12--246 vs. 3 monthsSignificant decrease in median PPPASI at week 24 in etanercept group; no significant difference between groups at 12 weeks (primary end point) (*p* = 0.426)No SAEs reported; Decreased PPPASI in 3/3 nonsmokers (increased PPPASI in 4/7 smokers) in etanercept group at 12 weeks  Lopez-Estebaranz 2010 \[[@CR29]\], case report1Etanercept 50 mg SC BIW for 12 weeks, then weekly for 12 weeks6 monthsAt week 12, complete resolution; maintained clearance for 6 months after discontinuation of etanerceptNo AEs reported  Kasche 2007 \[[@CR31]\], case report1Etanercept 25 mg SC BIW7 months"Sudden and dramatic improvement" at 2 weeks; restarted due to flare after d/c with "dramatic and rapid improvement" after 1 weekNo SAEs reported  Weinberg 2003 \[[@CR32]\], Case report1Etanercept 25 mg SC BIW19 weeksAt 19 weeks, "almost total clearing" of hands with "mild to moderate scaling" of feet, resolution of PsA symptomsNo AEs reported  Abourazzak 2014 \[[@CR49]\], case report1Etanercept 25 mg twice weekly12 monthsResolved; "good improvement within the first month"No AEs reportedInfliximab  Burgemeister 2012 \[[@CR20]\], case series2 (subset of 3 PPP)Infliximab (5 mg/kg q 8 weeks)Not reportedcomplete resolutionNo AEs reported  Aljuhani 2015 \[[@CR50]\], case series2 (subset of 20 PPP)(1) Infliximab; (2) adalimumab, etanercept(1) 3 years; (2) 9 months(1) completely resolved;\
(2) no response to adalimumab, then switched to etanercept with no responseNo AEs reported  Yawalkar 2009 \[[@CR36]\], Case report1Infliximab 5 mg/kg IV at weesk 0, 2, 6; then at week 14 adalimumab 40 mg SC q 2 weeks then 40 mg SC weekly6 weeks infliximab, then ≥ 3 months adalimumab"Marked improvement" at 2 weeks with recurrence at week 14; slower but satisfactory clinical response with adalimumab1 SAE: infusion related reaction with polyarthalgia, myalgia and fever at week 6 leading to discontinuation  Fairhurst 2008 \[[@CR38]\], Case report1Infliximab 5 mg/kg IV at weesk 0, 2, 66 weeks"Dramatic improvement" after first 2 infusions, "deterioration" after third infusion1 SAE: autoimmune hepatitis  Barland 2003 \[[@CR40]\], Case report1Infliximab 5 mg/kg IV monthly months 0--4, infliximab 10 mg/kg IV monthly months 5-6, then infliximab 10 mg/kg IV monthly + methotrexate 7.5 mg PO weeklyNot reportedInitial "dramatic response" followed by relapse; addition of methotrexate led to "virtually absent" lesions within 2 weeks with "lasting remission"No AEs reportedUstekinumab  Torre 2017 \[[@CR53]\], case report1Adalimumab (40 mg SC every other week × 4 months then 40 mg weekly × 6 months) + mycophenolate + Ustekinumab (90 mg on day after 10 months at days 1, 28, then q 3 months)14 months95% clearance after 14 monthsNo AEs reported  Pinto-Almeida 2013 \[[@CR46]\], Case report1Ustekinumab 45 mg SC at weeks 0, 4, and every 12 weeks thereafter12 monthsClinical improvement noted at 3 weeks and clearance achieved at 16 weeks; sustained response at 12 monthsNo AEs reported  de Unamuno-Bustos 2011 \[[@CR47]\], Case report1Ustekinumab 45 mg SC q 12 weeks8 monthsAfter 2 doses "almost complete clearance"; remained clear of lesions at 8 monthsNo AEs reported  Gerdes 2010 \[[@CR48]\], case series4Ustekinumab 45 mg or 90 mg (if ≥ 100 kg) SC q 12 weeks2 months to unclearFailure in 2 subjects (1 and 2); slow improvement in 1 subject (palms clear but soles still affected at 3 months); decreased pustules and involved area of both soles at 3 months in 1 subjectNo AEs reported Table 4Hyperkeratotic PP, pustular PP, and/or PPP, efficacy and safety of biologic agentsReference, type of studyNumber of subjectsTreatmentTreatment durationOutcomeSafety/commentsAdalimumab  Richetta 2012 \[[@CR19]\], open label study11 (hyperkeratotic or pustular PP; variant not reported)Adalimumab (40 mg q 2 weeks)12 weeksPGA improvement 54.5%, mean PGA: 1.09, PGA 0 36.1%;\
DLQI improvement: 72.3%, mean DLQI: 7.45, ≥ 50% DLQI improvement 45.5%No AEs reportedAnakinra  Tauber 2014 \[[@CR52]\], case report(1) pustular PP,\
(2) hyperkeratotic PPAnakinra (100 mg SC)(1) 3 months;\
(2) 1 month(1) Partial response to PPASI 20.7 and DLQI 13 at 2 weeks but relapsed at 3 months, stopped due to lack of efficacy/recurrence\
(2) Partial response to PPASI 13.5 at 1 mo, stopped due to fever without cause(1) relapse of pustular lesions;\
(2) AE of feverEtanercept  Spuls 2003 \[[@CR26]\], Case series1 (etanercept) and 1 (infliximab) (subset of 26 patients with PP; hyperkeratotic or pustular variant not reported)(1) Etanercept;\
(2) infliximabNot described(1) Complete resolution\
(2) Complete resolutionNo AEs reportedInfliximab  Di Lernia 2010 \[[@CR34]\], Case series3 (hyperkeratotic PP),\
1 (PPP)Infliximab 5 mg/kg IV at weesk 0, 2, 6 and every 8 weeks thereafter10--16 monthsAt 16 weeks, (1) PPPAS- 100; (2) and (3) PPPASI-75; (4) PPPASI-501 SAE: infusion-related urticarial reaction in patient 2 at week 46 leading to discontinuationUstekinumab  Bissonnette 2013 \[[@CR11]\], Double-blind randomized placebo-controlled trial10 (pustular PP),\
5 (PPP)1:1 ustekinumab 45 mg SC at weeks 0, 4, and 16 vs. placebo at weeks 0 and 4, then ustekinumab 45 mg SC at weeks 16 and 2028 weeks (primary endpoint at week 16)At week 16, 10% of subjects with pustular PP achieved PPPASI-50 vs. 20% in placebo group (*p* = 1.00); 20% of subjects with PPP achieved PPPASI-50 vs. 37.5% in placebo group (*p* = 1.00)No SAEs reported; 1 leg cellulitis (possibly related) and 1 pneumonia (unrelated)  Au 2013 \[[@CR10]\], Open-label prospective trial10 (hyperkeratotic PP),\
10 (pustular PP)Ustekinumab 45 mg for body weight \< 100 kg, 90 mg for body weight ≥ 100 kg SC at weeks 0, 4, 1616 weeksAt week 16, 35% (7/20) achieved clinical clearance, 60% (12) Palm-Sole PGA improved ≥ 2 pointsNo related SAEs reported; 67% receiving 90 mg achieved clinical clearance vs. 9% of those on 45 mg  Bertelsen 2014 \[[@CR54]\], Case series6 (pustular PP),\
5 (PPP)Ustekinumab 45 mg SC at weeks 0, 4, and every 12 weeks thereafterUp to 44 monthsPustular PP: 1 Complete resolution (1), partial response (3), no response (1), progression (1);\
PPP: Partial response (3), no response (1), progression (1)Flu-like symptoms, headache, fatigue (1); no difference reported in response between patients with palmoplantar pustular psoriasis and palmoplantar pustulosis*AE* Adverse event, *BSA* body surface area, *DLQI* Dermatology Life Quality Index, *F* female,*hfPGA* Physician Global Assessment of the hand and foot, *HTN* hypertension,*IGA* Investigator Global Assessment,*IM* intramuscular, *IV* intravenous, *M* male, *m-PPPASI* modified Palmoplantar Pustulosis Area and Severity Index, *PASI* Psoriasis Area and Severity Index, *PGA* Physician Global Assessment,*PO* orally, *PP* palmoplantar psoriasis,*PPIGA* palmoplantar psoriasis Investigator Global Assessment, *PPP* palmoplantar pustulosis,*PsA* psoriatic arthritis, *PUVA* psoralen + ultraviolet A,*q* every,*RCT* randomized controlled trial, *SAE* serious adverse event, *SC* subcutaneous, *URI* upper respiratory infection *UVA* ultraviolet A, *UVB* ultraviolet B^a^Primary endpoint of study

Efficacy {#Sec7}
--------

The results of each publication are summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The characteristics describing each study are reported in Tables S1, S2, S3, and S4. The proportion of patients demonstrating clinical improvement is reported in Table [5](#Tab5){ref-type="table"}.Table 5Clinical improvement of palmoplantar psoriasis or palmoplantar pustulosis following treatment with biologic agentMedicationVariant treatedTotal number of casesCases in which patients demonstrated improvement^a^Serious adverse eventsAdalimumabHyperkeratotic PP \[[@CR14], [@CR15]\]150142 (94.7%)No SAEs reportedPustular PP \[[@CR24]\]11 (100.0%)No SAEs reportedPPP \[[@CR22], [@CR23], [@CR50], [@CR53]\]72 (28.6%)No SAEs reportedTotal^b^169152 (89.9%)AlefaceptHyperkeratotic PP \[[@CR21]\]22 (100.0%)No SAEs reportedPustular PP00PPP00Total22 (100.0%)AnakinraHyperkeratotic PP \[[@CR52]\]11 (100.0%)No SAEs reportedPustular PP \[[@CR52]\]11 (100.0%)No SAEs reportedPPP00Total22 (100.0%)EtanerceptHyperkeratotic PP \[[@CR17], [@CR25]\]6041 (68.3%)No SAEs reportedPustular PP \[[@CR27], [@CR28], [@CR30]\]32 (66.7%)Reactivation of latent TBPPP \[[@CR12], [@CR22], [@CR29], [@CR31], [@CR32], [@CR49]\]2313 (56.5%)No SAEs reportedTotal^b^8757 (65.5%)GuselkumabHyperkeratotic PP \[[@CR15]\]10090 (90.0%)No SAEs reportedPustular PP00PPP00Total10090 (90.0%)InfliximabHyperkeratotic PP \[[@CR13], [@CR33], [@CR34]\]3224 (75.0%)Cellulitis, hepatitis, infusion-related urticarial reactionPustular PP \[[@CR35], [@CR37], [@CR39]\]84 (50.0%)PPP \[[@CR20], [@CR22], [@CR34], [@CR36], [@CR38], [@CR40], [@CR50]\]88 (100.0%)Serum sickness-like infusion reaction, autoimmune hepatitisTotal^b^4937 (75.5%)IxekizumabHyperkeratotic PP \[[@CR17]\]206170 (82.5%)No SAEs reportedPustular PP00PPP00Total206170 (82.5%)SecukinumabHyperkeratotic PP \[[@CR16], [@CR18]\]18363 (89.1%)150 mg 5.9% SAE, 300 mg 2.9% SAE, placebo 2.9% SAE^c^Pustular PP00PPP00Total18363 (89.1%)UstekinumabHyperkeratotic PP \[[@CR10], [@CR41]--[@CR43]\]1513 (86.7%)No SAEs reportedPustular PP \[[@CR10], [@CR11], [@CR45], [@CR51], [@CR54]\]4022 (55.0%)No SAEs reportedPPP \[[@CR11], [@CR46]--[@CR48], [@CR53], [@CR54]\]1710 (58.8%)No SAEs reportedTotal7245 (62.5%)*SAE *serious adverse event^a^Using most conservative estimate \[PPASI-50 if available; otherwise, if reported, a PPASI-75 or an IGA score of 0/1 (cleared/minimal disease)\]^b^Includes data from Richetta et al. \[[@CR19]\], and Spuls et al. \[[@CR26]\] in which specific morphology is not described^c^No SAEs were fatal, no cardiac events, and no opportunistic infections

Hyperkeratotic PP {#Sec8}
-----------------

In the RCT performed by Leonardi et al. \[[@CR14]\], a greater number of patients with hyperkeratotic PP treated with adalimumab achieved a clinical score of clear or almost clear at 16 weeks compared to patients treated with placebo (30.6% vs. 4.3%; *p* = 0.01). Response was maintained at 28 weeks by 80% of these subjects. Of the patients in the RCT or case reports who were treated with adalimumab, 94.7% demonstrated an overall clinical improvement. In another RCT by Bissonnette et al. \[[@CR13]\], a greater proportion of patients with hyperkeratotic PP treated with infliximab achieved at least a 50% reduction in clinical severity at 14 weeks compared to patients treated with placebo (66.7% vs. 8.3%; *p* = 0.01). These authors also reported that infliximab was superior to placebo in the reduction of mean area of involvement (50 decrease vs. 15% increase; *p* = 0.01). Overall, 75% of all patients studied using infliximab demonstrated clinical improvement. In their clinical trial, Blauvelt et al. \[[@CR15]\] observed a significant clinical clearance among those patients treated with guselkumab when compared to those receiving placebo at 16 weeks (85.1% reaching an IGA score of 0 or 1; *p* \< 0.001). Clinical improvement was observed in 90% of all patients studied receiving treatment with guselkumab. In three phase 3 trials conducted by Menter et al. \[[@CR17]\], a greater proportion of the patients treated with ixekizumab showed clinical improvement compared to those treated with etanercept or those receiving placebo (PPASI-50: 80 vs. 67.8 vs. 32.9, respectively; *p* \< 0.05). Overall, 82.5% of the patients studied who were using ixekizumab demonstrated clinical improvement. Significant clinical clearance was achieved in a RCT that compared secukinumab at a dose of 300 or 150 mg to placebo \[palmoplantar psoriasis IGA (PPIGA) score of 0 or 1: 33.3% (300 mg dose), 22.1% (150 mg dose), vs. 1.5%; *p* \< 0.001 and *p* = 0.002, respectively\] \[[@CR16]\]. The proportion of patients in all studies demonstrating clinical improvement after completing treatment with secukinumab was 89.1%. In an uncontrolled open label study of ustekinumab, 20% patients with hyperkeratotic PP achieved clinical clearance after 16 weeks of therapy \[[@CR10]\]. Clinical clearance was achieved by 50% of patients receiving a 90 mg dosage regimen, while no patients receiving a 45 mg regimen achieved clearance.

A number of case series and case reports describe effective treatment of hyperkeratotic PP with etanercept, alefacept, infliximab, and ustekinumab (Tables [1](#Tab1){ref-type="table"}, [4](#Tab4){ref-type="table"}) \[[@CR21], [@CR25], [@CR26], [@CR33], [@CR34], [@CR41]--[@CR43], [@CR52]\].

Pustular PP {#Sec9}
-----------

In a small RCT by Bissonnette et al. \[[@CR11]\], ustekinumab 45 mg was not superior to placebo in achieving at least a 50% reduction in clinical severity among patients with pustular PP after 16 weeks of therapy (*p* = 1.00). In an open label study by Au et al. \[[@CR10]\], half of the patients with pustular PP treated with ustekinumab achieved clinical clearance after 16 weeks of therapy. A greater proportion of patients receiving a 90 mg regimen of ustekinumab achieved clearance compared to those receiving a 45 mg regimen (80% vs. 20%). In another open label study, 54.5% of patients with pustular or hyperkeratotic PP who were treated with adalimumab reached clinical clearance after 12 weeks of therapy \[[@CR19]\].

In addition, case series and case reports describe effective treatment of pustular PP with adalimumab, etanercept, infliximab, and ustekinumab \[[@CR24], [@CR26], [@CR28], [@CR30], [@CR34], [@CR35], [@CR37], [@CR39], [@CR45], [@CR51], [@CR52], [@CR54]\]. In contrast, other case reports show ineffective treatment with adalimumab or mixed responses to ustekinumab (Tables [2](#Tab2){ref-type="table"}, [4](#Tab4){ref-type="table"}) \[[@CR27], [@CR54]\].

Palmoplantar Pustulosis {#Sec10}
-----------------------

In a RCT of patients with PPP conducted by Bissonnette et al. \[[@CR12]\], treatment with etanercept was not found to be superior to placebo at the primary endpoint of 12 weeks of therapy (*p* = 0.426). Interestingly, smoking may have played a role in treatment efficacy, as the authors noted that three of three nonsmokers achieved clinical improvement with etanercept therapy while only three of seven active smokers demonstrated improvement. In a small RCT by Bissonnette et al. \[[@CR11]\], ustekinumab 45 mg was not found to be superior to placebo at 16 weeks of therapy (*p* = 1.00).

Case reports and case series describe effective treatment of PPP with etanercept, infliximab, and ustekinumab \[[@CR20], [@CR29], [@CR31], [@CR32], [@CR46]--[@CR50], [@CR53], [@CR54]\]. Multiple reports of treatment with infliximab describe a period of initial improvement with eventual recurrence (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}) \[[@CR36], [@CR38], [@CR40]\].

Safety {#Sec11}
------

Serious adverse events (SAEs) were infrequently reported. The majority of cases occurred in patients treated with infliximab, and the SAEs included cellulitis, hepatitis, an urticarial infusion reaction, a serum sickness-like infusion reaction, and autoimmune hepatitis \[[@CR13], [@CR34], [@CR36], [@CR38]\]. One subject with a history of a positive tuberculin skin test developed reactivation tuberculosis while undergoing treatment with etanercept for pustular PP \[[@CR30]\]. In the GESTURE RCT that used secukinumab as treatment for hyperkeratotic PP, 5.9% of patients developed SAEs while on a 150 mg therapeutic regimen and 2.9% of patients developed SAEs while on a 300 mg therapeutic regimen, compared to 2.9% that developed SAEs while using placebo. However, the authors of this study did not report the statistical significance of the SAEs. None of these SAEs were cardiac-related, and there were no opportunistic infections or fatalities \[[@CR16]\].

Special Populations {#Sec12}
-------------------

Three patients with chronic hepatitis C virus (HCV) were treated with biologic medications for PP without hepatologic complications \[[@CR30], [@CR34], [@CR45]\]. One patient with chronic HCV displayed an infusion-related urticarial reaction during infliximab treatment, leading to discontinuation of the medication \[[@CR34]\]. One patient with comorbid untreated latent tuberculosis developed reactivation tuberculosis after 4 years of therapy with etancercept \[[@CR34]\]. One pediatric patient was treated with etanercept with no reported SAEs \[[@CR28]\].

Discussion {#Sec13}
==========

The advent of biologic medications has greatly enhanced the treatment of moderate to severe plaque psoriasis. Current evidence suggests that biologic agents may also be effective therapeutic options for the treatment of hyperkeratotic PP, with less evidence supporting their use in pustular PP and PPP.

For hyperkeratotic PP, results from RCTs (level 1 evidence) suggest that adalimumab, guselkumab, ixekizumab, infliximab, and secukinumab are effective treatment options. While ustekinumab has not been evaluated in a RCT of patients with hyperkeratotic PP, in an open label study (level 3 evidence), one-half of patients receiving a 90 mg regimen achieved clinical clearance.

For pustular PP, ustekinumab 45 mg did not appear to be more effective than placebo (level 1 evidence) in patients participating in a small RCT. However, the majority of patients (80%) with pustular PP receiving a 90 mg regimen of ustekinumab in an open label study did achieve clinical clearance \[[@CR10]\]. With the exception of ustekinumab, limited information on pustular PP treatment can be found in the literature. We found only eight pustular PP patients treated with infliximab, three patients with etanercept, and one patient each treated with adalimumab and anakinra. We found no reports of pustular PP treatment with alefacept, guselkumab, ixekizumab, or secukinumab. Of note, in all of the pustular PP case reports, patients were treated with the standard dose of biologic for plaque psoriasis. The lack of response in many of these cases suggests the possibility that pustular PP may require higher doses of biologics than hyperkeratotic PP or body plaque psoriasis in order to achieve efficacy.

For the treatment of PPP, the results of two small RCTs suggest that treatment with etanercept and ustekinumab 45 mg may not be more effective than placebo (level 1 evidence). However, the study of ustekinumab included only five patients in the active treatment arm, and no patient received a 90 mg regimen of this biologic \[[@CR11], [@CR54]\]. Overall, infliximab appeared to have the greatest efficacy for PPP compared to other biologics, followed by ustekinumab. It is important to note that the quality of these conclusions is limited since most of the data were from case reports or case series.

Although case series and case reports offer less rigorous evidence for the efficacy of biologic agents in PP and PPP, they do illustrate a few notable trends. For example, ustekinumab has been shown to be effective in multiple cases of PP and PPP refractory to tumor necrosis factor-alpha (TNF-α) inhibitor therapy \[[@CR10], [@CR43], [@CR45], [@CR47], [@CR48]\]. Additionally, infliximab appears to have a higher risk of SAEs compared to other biologics, and it may also demonstrate loss of efficacy over the course of treatment \[[@CR13], [@CR34], [@CR36]--[@CR38], [@CR40]\]. In one RCT, patients treated with secukinumab 150 mg showed a greater percentage of SAEs than those receiving placebo (5.9% vs 2.9%, respectively), but there was no dose effect, with the secukinumab 300 mg group having a SAE rate of 2.9%, which was identical to that of the group receiving placebo \[[@CR16]\]. These data indicate that secukinumab may not be truly associated with SAEs, since there is not an observable dose--response relationship or trend.

Importantly, while there have been reports of new-onset PPP or exacerbation of existing PPP during TNF-α inhibitor therapy \[[@CR55]--[@CR58]\], only one clearly reported case of exacerbation of PPP, in response to infliximab, was identified in our review of patients with baseline PP and PPP \[[@CR37]\]. In one RCT, four patients (40.0%) with PPP treated with etanercept experienced increases in disease severity over the first 12 weeks of treatment, but it is not clear whether these were drug-induced exacerbations or simply reflective of a nonresponse to treatment and disease progression \[[@CR12]\].

Notably, two recent studies based on subanalysis of Phase II data for secukinumab demonstrated high rates of response among patients with hyperkeratotic PP, with up to 71% of patients achieving clinically significant improvement \[[@CR59], [@CR60]\]. Further studies of novel biologic agents developed for the treatment of moderate to severe plaque psoriasis may yield new therapeutic options for PP and PPP.

The difference in response to biologics observed between PP and PPP may be explained by some notable differences in their genetic profiles. The psoriasis susceptibility gene locus (*PSORS1*) that is strongly linked to psoriasis is not found in patients with PPP. Additionally, both a missense mutation in the interleukin (IL)-36 receptor antagonist (IL36RN) and caspase recruitment domain family member 14 (CARD14) have been identified in patients with PPP, which could influence patient response to treatment with biologics \[[@CR9], [@CR61]\]. However, both PP and PPP involve IL-17 as a mediator of inflammation, in addition to interferon-gamma and TNF-α. The shared histologic features of the diseases, consisting of spongiform pustules and inflammatory infiltrates, may account for some of the overlap in treatment response and clinical appearance \[[@CR7], [@CR9]\]. There is a need for future studies to explore these genetic differences further.

Several limitations to our analysis make it difficult to assess the efficacy of biologic medications in PP and PPP. First, patients with PP and PPP are often excluded from clinical trials due to recruitment requirements that patients be diagnosed with stable plaque psoriasis with no pustular component and demonstrate involvement of at least 10% of the body surface area. Second, some of the RCTs using biologics for these skin diseases, especially for pustular PP, although completed, are not published yet and therefore could not be included in our review. Third, reporting bias in case reports and case series makes it difficult to determine the true rates of response to biologic agents. Fourth, differences in the use of metrics to quantify the severity of PP and PPP impose challenges when comparing rates of response across studies. In addition, only one small RCT was available for pustular PP and another for PPP, with the majority of RCTs specific to hyperkeratotic PP.

Currently, a number of different scales are used to assess the severity of PP and PPP, and in many case reports and case series no metrics are used at all. Future studies should attempt to standardize the heterogeneity of clinical metrics to allow for a more rigorous comparison of the efficacy of biologic medications in PP and PPP. In some RCTs, only mean changes in clinical scores are reported without information on patient-specific responses. In the most basic schema, the number of patients who achieve clearance and the number who demonstrate objective improvement should be reported. Further, studies should consistently report the presence or absence of psoriasis at other body areas and stratify results based on this information.

Nonetheless, patient reported outcomes and functional metrics, such as the survey developed by Farley et al., may be more important than visual metrics in evaluating response to treatment in PP and PPP \[[@CR5]\]. Complete clearance may not be necessary if patients achieve sufficient improvement to perform activities of daily living and occupational tasks without pain or discomfort \[[@CR2]\].

Conclusion {#Sec14}
==========

Overall, biologics are effective and well-tolerated for the treatment of hyperkeratotic PP, as demonstrated by the \> 80% efficacy for adalimumab, guselkumab, ixekizumab, secukinumab, and ustekinumab. The strong support for effective hyperkeratotic PP treatment is derived from multiple large RCTs, and thus providers may consider tailoring their treatment to include biologics earlier when a patient presents with this recalcitrant chronic disease. Infliximab and ustekinumab showed moderate efficacy for pustular PP, but the data were limited to small trials or case reports. Less data are available for the treatment of PPP; however, to date infliximab is the most efficacious treatment. Future studies are needed to further assess the efficacy of biologic medications in the treatment of PP and PPP. In addition, future research should be performed to compare the efficacy and safety of biologics with traditional systemic therapy and phototherapy for these debilitating and therapeutically challenging conditions.
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